Quell Therapeutics strengthens its Board with the appointments of Dr Dhaval Patel and Sir Robert Lechler and hires Dr Natalie Belmonte as SVP Research & Translation
London – June 11 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the appointments of seasoned industry expert, Dr Dhaval Patel, Executive Vice President and Chief Scientific Officer UCB S.A. (Brussels, Belgium),…...
Read MoreQuell Therapeutics Enters a Collaborative Research Agreement with the Hannover Medical School
Collaboration will accelerate Quell’s pipeline expansion into autoimmune and inflammatory diseases London and Hannover – April 7 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a…...
Read MoreT regs are back – promising to do for autoimmunity what CAR Ts have done in cancer
The following article was published in BioCentury Drug developers are giving regulatory T cells a second look as treatments for autoimmune disease. The difference this time is that they can leverage orthogonal benefits from CAR T cells in cancer, capitalizing on new…...
Read MoreQuell Therapeutics named a “Fierce 15“ Company by FierceBiotech
London, 23 September 2019 – Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private…...
Read MoreQuell Therapeutics, founded by Syncona Ltd, appoints Chief Executive
Building a team of leading experts in the field of Regulatory T cell-based therapy and biology London, 13 June 2019 – Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces the appointment of Iain McGill,…...
Read More